1 / 5

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA)

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD. Aim

kendrasimpson
Download Presentation

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Proposed comprehensive ototoxicity monitoring program for VAhealthcare (COMP-VA) Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD

  2. Aim • Describe COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. • Relevance • With improved survivability following cancer treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.

  3. Method • COMP-VA is designed to be administered on chemo-therapy treatment unit just before treatment (chairside). • Uses portable ototoxicity identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.

  4. Clinical Objectives • Pretreatment ototoxicity risk assessment. • Behavioral screening for early hearing changes. • Screening for outer hair cell dysfunction. • Nonbehavioral screening for early hearing changes. • Screen failure follow-up testing. • Screening for tinnitus. • Patient and provider education about ototoxic-induced hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.

  5. Conclusion • Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the-minute estimates of ototoxicity before patient’s next treatment. • This allows for timely consideration of treatment changes. • Program encourages efficient communication and team relationships between audiology and oncology.

More Related